We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Sensitive Blood Test Diagnoses Heart Attacks Faster

By LabMedica International staff writers
Posted on 23 Aug 2018
A high-sensitivity (hs) troponin T (cTnT) assay that has greater sensitivity and precision than the conventional fourth-generation cTnT assay currently in use in the USA has been recently approved.

The new high-sensitivity blood test for cardiac troponin, given in a hospital emergency room, was also found to be safe and effective. More...
When patients present to emergency rooms with heart attack symptoms, doctors assess them in part by using a cardiac troponin test to measure a protein released into the blood when the heart is damaged.

Scientists at the University of Texas (UT) Southwestern Medical Center (Dallas, TX, USA) and their colleagues developed a procedure for assessing the results of the new test and compared it to existing practice using a conventional troponin test, which takes three hours to complete. Study participants were 536 patients admitted to an emergency room with heart attack symptoms, including chest pains and shortness of breath.

The team reported that in the cohort (mean age 55 years, 44% women), the final adjudicated diagnosis was myocardial infarction (MI) in 2.1%, unstable angina in 0.4%, and nonischemic myocardial injury in 17.0%. With the conventional assay, 80.4% of patients ruled out for MI at three hours. With the new hs-cTnT protocol, 83.8% ruled out by three hours, including 30.0% at baseline, 24.8% at one hour, and 28.9% at three hours. Compared with 19.6% of patients considered abnormal by the conventional assay, 16.2% of patients were abnormal under the new protocol.

Rebecca Vigen, MD, a cardiologist and lead author of the study, said, “We did not miss any heart attacks using this test in this population. The test also allowed us to determine faster that many patients who had symptoms of a heart attack were not having a heart attack than if we had relied on the traditional test. We anticipate that this procedure will allow many patients with chest pain to be given a 'yes' or 'no' diagnosis of whether they are having a heart attack faster.” The study was published on August 6, 2018, in the journal Circulation.

Related Links:
University of Texas (UT) Southwestern Medical Center


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.